A 24‐week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis

摘要: Summary Background  Nail psoriasis is common in patients with and can seriously affect their quality of life. Current treatments are limited there no standard course therapy. Objectives  To assess the efficacy safety etanercept (ETN) on nail moderate-to-severe psoriasis. Methods  Patients plaque psoriasis, who had previously failed at least one form systemic therapy for were randomized to receive open-label ETN 50 mg twice weekly (BIW) 12 weeks followed by once (QW) (BIW/QW group) or QW 24 weeks (QW/QW group). The primary endpoint was mean improvement Psoriasis Severity Index (NAPSI; score range 0–8) over target fingernail most severe abnormalities. Results  Seventy-two received more doses (38 BIW/QW; 34 QW/QW) 69 included modified intent-to-treat population. At baseline, (standard error) NAPSI 6·0 (0·3) BIW/QW group 5·8 QW/QW group. week 24, decreased significantly −4·3 [95% confidence interval (CI) −4·9 −3·7; P < 0·0001] −4·4 (95% CI −5·0 P < 0·0001) Improvement showed significant correlation Area improvement. well tolerated unexpected findings. Conclusions  Both regimens effective treating this patient